Incyte Corporation reported second quarter 2026 financial results with total revenue of $1.67 billion and total net sales of $1.49 billion, representing increases of 38% and 40% respectively compared to the prior year period. Net sales growth was significantly impacted by a one-time, non-cash benefit of $246 million from the reversal of accrual balances related to a CMS settlement regarding Opzelura. Excluding this benefit, total net sales grew 17%. Jakafi net sales increased 7% to $817 million, while Opzelura net sales surged 173% to $450 million. The company raised its full-year 2026 total net sales guidance to $5.13–$5.26 billion and operating expense guidance to $4.915–$4.995 billion, reflecting the CMS agreement impact and the acquisition of Vega Therapeutics for $1.25 billion. Incyte operates in the biopharmaceutical industry, developing and commercializing medicines for hematology, oncology, and inflammation.
